Zoetis (NYSE:ZTS) Given “Overweight” Rating at Piper Sandler

Zoetis (NYSE:ZTS)‘s stock had its “overweight” rating reaffirmed by research analysts at Piper Sandler in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $195.00 price objective on the stock, down from their previous price objective of $220.00. Piper Sandler’s target price points to a potential upside of 28.34% from the company’s previous close.

ZTS has been the subject of a number of other reports. Jefferies Financial Group reiterated a “buy” rating and set a $230.00 price objective on shares of Zoetis in a research report on Tuesday, December 19th. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Stifel Nicolaus lowered their price objective on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. The Goldman Sachs Group upped their price objective on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Finally, Barclays upped their price objective on shares of Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 14th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $221.75.

Zoetis Stock Performance

Shares of Zoetis stock opened at $151.94 on Tuesday. The company has a 50 day moving average of $177.35 and a 200-day moving average of $180.39. Zoetis has a 1-year low of $148.48 and a 1-year high of $201.92. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The company has a market cap of $69.49 billion, a PE ratio of 29.97, a price-to-earnings-growth ratio of 2.29 and a beta of 0.85.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. Zoetis’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.15 earnings per share. As a group, equities research analysts forecast that Zoetis will post 5.8 earnings per share for the current fiscal year.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $197.74, for a total value of $71,779.62. Following the completion of the transaction, the executive vice president now directly owns 20,417 shares in the company, valued at approximately $4,037,257.58. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.15% of the company’s stock.

Institutional Investors Weigh In On Zoetis

Large investors have recently modified their holdings of the company. Blue Bell Private Wealth Management LLC increased its position in shares of Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after buying an additional 89 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in shares of Zoetis by 430.8% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after buying an additional 112 shares during the period. VitalStone Financial LLC acquired a new stake in shares of Zoetis during the first quarter worth $37,000. Evermay Wealth Management LLC boosted its stake in Zoetis by 439.3% during the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after acquiring an additional 123 shares in the last quarter. Finally, Worth Asset Management LLC bought a new position in Zoetis during the first quarter worth $26,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.